the influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 • 2,616 citations

Interleukin-2: Inception, Impact, and Implications

1988 • 2,166 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

1986 • 459 citations

Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells

1988 • 353 citations

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

1989 • 240 citations

New Approaches to the Immunotherapy of Cancer Using Interleukin-2

1988 • 202 citations

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1988 • 200 citations

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1988 • 159 citations

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.

1988 • 138 citations

Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.

1986 • 116 citations

Interleukin-2 in cancer therapy.

1988 • 115 citations

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

1988 • 110 citations

Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.

1988 • 87 citations

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors.

1989 • 78 citations

Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.

1989 • 72 citations

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.

1989 • 56 citations

A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.

1988 • 54 citations

Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans.

1988 • 32 citations

In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies.

1990 • 29 citations

Addition of interleukin-2in vitro augments detection of lymphokine-activated killer activity generatedin vivo

1990 • 27 citations

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

1989 • 23 citations

The cellular immunotherapy of cancer: Current and potential uses of interleukin-2

1989 • 12 citations